Primary care in Gloucestershire

Gloucestershire's primary-care market is substantial, but its defining feature is not a simple lack of providers. It is the combination of an ageing population, very different urban and rural access patterns, increasing long-term-condition complexity and an NHS system deliberately shifting more care into neighbourhoods.

The county's current NHS structure includes 16 Primary Care Networks (PCNs) aligned to six Integrated Locality Partnerships. The 2025–28 Pharmaceutical Needs Assessment (PNA) includes a January 2025 district table showing 105 community pharmacies, but its later May 2025 current-provision snapshot records 103 community pharmacies, 30 dispensing doctors, two dispensing appliance contractors and two distance-selling pharmacies. May 2025 is the more recent published contractor count; neither date is a live October 2026 register. The final PNA concludes there are no current gaps in necessary pharmaceutical services county-wide.

The NHS is also changing the shape of dental access. A new seven-surgery Dental Access Centre opened at Quayside House in Gloucester on 1 July 2026, while a further dental school and treatment hub has been announced, with the operational opening date requiring confirmation.

For a prospective healthcare provider, these developments point to a more precise question than whether Gloucestershire needs “more primary care”: which population, pathway or locality has an access problem that a new service can solve without duplicating existing NHS capacity?

Gloucestershire's six locality markets

The county combines Gloucester, Cheltenham, Stroud and Berkeley Vale, Tewkesbury, the Cotswolds and the Forest of Dean.

Gloucester contains dense urban neighbourhoods with marked differences in deprivation and health outcomes. Cheltenham has established urban practices and mixed income groups. Stroud and Berkeley Vale combine towns, industrial communities and rural catchments. The Cotswolds and Forest of Dean include communities where distance, transport and dispensing arrangements matter considerably. Tewkesbury combines market-town demand with growth and rural access considerations.

This means a county-wide pharmacy-to-population ratio or GP satisfaction figure cannot establish the business case for a specific site. A service designed for Gloucester's inner city may need a different access, pricing and referral model from one serving rural patients around Stow-on-the-Wold or Coleford.

The 16 PCNs are the practical organising units

NHS Gloucestershire's current directory identifies 16 PCNs across six localities:

• Cheltenham: Central, Peripheral and St Paul's.
• Cotswolds: North Cotswolds and South Cotswolds.
• Forest of Dean: Forest Green and West Forest of Dean.
• Gloucester City: Aspen, Inner City, North and South Gloucester, Rosebank, and Hadwen & Quedgeley.
• Stroud & Berkeley Vale: Berkeley Vale, Severn Health and Stroud Cotswold.
• Tewkesbury: Tewkesbury, Newent & Staunton.

The NHS directory shows most PCNs serving populations of roughly 30,000 to 60,000 patients. Individual list sizes vary and are not the same as the county's resident population: registered patients may cross local authority boundaries.

For market analysis, the network is often a better unit than the county. It provides a more meaningful way to understand GP relationships, multidisciplinary capacity, community services and neighbourhood-level demand.

A new provider should identify the relevant practices and PCN for its proposed catchment rather than send generic approaches to every surgery in Gloucestershire.

GP access is pressured, but satisfaction is relatively strong

The July 2026 NHS Gloucestershire report on the national GP Patient Survey found 81% overall satisfaction with local GP practices, compared with 77% across England.

1. Gloucestershire81%
2. England77%

7484

This is positive evidence and should not be obscured by generic claims that local general practice is failing. It does not mean that every patient can obtain the appointment they want, or that all localities experience equivalent access.

The same 2026 report recorded 89% positive experiences of community pharmacy services and 69% for NHS dental services. Those are survey experience measures, not clinical capacity figures.

A new private GP clinic cannot infer a viable market solely from national news about GP waiting times. It needs local evidence of patient willingness to pay, appointment preferences, continuity needs and competition from NHS access improvements.

General practice is no longer only a GP-led appointment model

Gloucestershire's PCNs bring together practices with other professionals including pharmacists, physiotherapists, paramedics, mental-health practitioners and social-prescribing teams.

This matters commercially. A service previously assumed to require a GP appointment may increasingly be delivered through a multidisciplinary team, community pharmacy, diagnostics pathway or neighbourhood hub.

For example, a private provider considering minor illness, musculoskeletal care or medication review must identify which elements are already available without direct patient payment through existing local services.

The more durable opportunity may be a particular clinical pathway, extended-hours access, complex assessment or partnership service rather than another generic appointment offer.

The 2026–31 NHS plan changes the market outlook

NHS Gloucestershire's Population Health and Strategic Commissioning Plan 2026–2031 identifies three major shifts: prevention, care closer to home and better use of digital technology.

It proposes organising proactive care around neighbourhoods of approximately 30,000–50,000 people, aligned to PCNs, and developing Integrated Neighbourhood Teams for people at risk of deteriorating health.

The plan also envisages local hubs operating for extended hours, greater use of community diagnostics and services that adjust support as patients recover.

These are strategic ambitions, not proof that every proposed hub or contract is already operational.

For independent providers, the implication is to design services that can integrate with neighbourhood pathways. A standalone clinic that duplicates existing NHS provision may face greater competition as the plan develops.

An ageing county creates more complexity, not only more appointments

The NHS plan describes Gloucestershire as a comparatively healthy county that is growing and ageing. More older residents will live with several long-term conditions and require coordinated support.

Primary-care demand therefore includes cardiovascular risk, diabetes, respiratory disease, frailty, dementia, medicines optimisation, falls prevention and palliative care.

The commercial opportunity depends on whether the service is already provided through general practice, community nursing, hospital outreach, pharmacy or commissioned specialist care.

For a new provider, a specific service such as frailty assessment, community diagnostics or long-term-condition monitoring needs a clearly defined referral pathway and clinical governance. Population ageing is a demand driver, not a purchasing agreement.

Urban deprivation and rural access create different needs

Gloucester City contains neighbourhoods with significant deprivation and access inequalities. The Cotswolds and Forest of Dean create different barriers: travel distance, public transport, rural isolation and the practical need for dispensing-doctor provision.

A county-wide service can therefore be inequitable even when the total number of facilities appears sufficient.

For urban communities, outreach, language support, continuity and affordability may matter most. For rural patients, travel time, appointment timing, home visits and reliable medication supply may be decisive.

Providers should assess the catchment using small-area population data, travel times, existing service opening hours and patient feedback rather than a single county average.

The 2025–28 PNA is the starting point for pharmacy analysis

Gloucestershire's PNA 2025–28 is the statutory evidence base for assessing local pharmaceutical provision. It considers population needs, existing contractors, access, distribution and possible future requirements.

Its January 2025 district table records 105 community pharmacies and 30 dispensing-doctor locations. Its later May 2025 supply snapshot records 103 community pharmacies and 30 dispensing doctors, alongside two distance-selling pharmacies and two dispensing appliance contractors. The January figures are useful for the district comparison, but the May figures are the most recent published county totals within the final PNA. The PNA finds no current gaps in necessary provision and anticipates no additional necessary provision arising from planned housing growth during the assessment period. This is a statutory sufficiency conclusion, not a guarantee that all residents experience convenient access.

The PNA's pharmacy density calculation was 15.9 community pharmacies per 100,000 residents, below the England comparator of 20.8 in the same table.

1. Gloucestershire15.9
2. England20.8

1422

That difference does not establish a statutory gap. The PNA explicitly notes that there is no recommended universal minimum number of pharmacies per population.

The market-entry question is therefore not “Why does Gloucestershire have fewer pharmacies per head?” It is “Does the statutory assessment identify a need or improvement in a particular location or service, and what is the relevant NHS market-entry route?”

Pharmacy provision varies materially by district

The PNA's historical January 2025 district comparison is as follows; the later May 2025 county total is 103 pharmacies, so do not treat the table as a current provider register:

The PNA table uses a mid-2023 population estimate for the rates and January 2025 contractor counts. Do not compare these ratios directly with a later population estimate without recalculating them.

Stroud has the lowest community-pharmacy density in this table, but dispensing doctors also provide medicines access. The Forest of Dean has fewer community pharmacies than Gloucester yet substantially more dispensing-doctor locations.

This demonstrates why provider density alone can misrepresent local access.

Rural dispensing changes the interpretation of pharmacy gaps

Dispensing doctors serve eligible patients in controlled localities where the relevant regulatory criteria are met. They are especially important in rural Gloucestershire.

The PNA's district table records nine dispensing-doctor locations in the Cotswolds, 13 in the Forest of Dean, six in Stroud and two in Tewkesbury, with none in Gloucester or Cheltenham.

A new pharmacy proposal should therefore account for existing GP dispensing, nearby pharmacies, distance-selling services, travel times and actual patient use.

It would be misleading to treat the absence of a high-street pharmacy in every village as evidence that an NHS pharmacy contract is available there.

Podsmead illustrates how local access evidence can change

In March 2025, the Gloucestershire Health and Wellbeing Board discussed an earlier PNA finding that had identified an opportunity to improve access in Podsmead, Gloucester. Members were told a new pharmacy was expected to open, addressing that historic issue.

The previous 2022–25 PNA had otherwise identified no general gaps in necessary services, according to the Board's March 2025 minutes.

The final 2025–28 PNA expressly records that Allied Pharmacy opened in Podsmead in July 2025, resolving the earlier access issue. It also finds no remaining gaps in necessary pharmaceutical services across Gloucestershire and no additional provision required for anticipated housing growth in the PNA period. Podsmead must therefore not be advertised as an open shortage. The important distinction is between an older unmet-access concern, a subsequent provider opening, and the latest statutory assessment.

This is a useful example of why dated, location-specific evidence is essential in healthcare market reports.

Community pharmacy is increasingly a clinical service

The traditional view of pharmacy as mainly dispensing medicines is incomplete. Pharmacy First, vaccinations, hypertension case-finding, contraception and medicines-related consultations make pharmacies an important route into NHS primary care.

A Gloucestershire Integrated Care System performance report discussed in 2026 recorded around 83,000 community-pharmacy clinical consultations in 2025/26, an increase of approximately 41% on the previous year.

83,000

Consultations in 2025/26

41%

Increase on the previous year

That figure reflects activity over a reporting year, not the number of unique patients or unmet appointments.

For an independent minor-illness clinic, pharmacy provision is a direct part of the competitive landscape. For a pharmacy operator, additional clinical services create opportunities but also staffing, consultation-room, training and commissioning requirements.

Pharmacy patient experience is positive but not universal

NHS Gloucestershire reported that 89% of respondents in the 2026 GP Patient Survey described positive community-pharmacy experiences.

Healthwatch Gloucestershire's earlier pharmacy work gathered local experiences of closures, medicines shortages, communication between GP practices and pharmacies and awareness of Pharmacy First. Its survey found that many respondents preferred face-to-face access.

These findings help identify service-design questions: is the problem geographical availability, opening hours, medicine supply, communication or awareness of services?

A new provider should avoid treating every reported inconvenience as proof of a market-wide capacity shortage. The remedy may be better communication or service delivery within existing provision.

NHS dentistry is a particularly active market

Gloucestershire has experienced difficulties with access to NHS dentistry, and the ICB has been investing in additional urgent and stabilisation appointments.

In August 2025 the ICB reported an average of 140 urgent appointments per week and more than 270 stabilisation appointments per week. By December 2025 it reported more than 360 weekly stabilisation appointments.

1. Urgent, August 2025

   140

2. Stabilisation, August 2025

   270+

3. Stabilisation, December 2025

   360+

These are dated operational reports, not a guarantee of identical availability in October 2026. They nevertheless show a system expanding supply.

For a prospective dental provider, NHS need and private-pay opportunity must be assessed separately. NHS activity depends on contracts, commissioning and workforce; private demand depends on household affordability, patient preferences and existing practices.

Gloucester's Dental Access Centre opened in July 2026

The Quayside House Dental Access Centre opened on 1 July 2026 with seven treatment rooms.

It provides urgent NHS dental appointments accessed through NHS 111, including some evening and weekend provision, with stabilisation and follow-up care where appropriate. The ICB contracted Smile Together CIC to operate the service.

This is not merely a proposal or an unfilled gap. It is additional capacity already opened.

A new dental business in Gloucester must account for this centre when forecasting urgent-care demand, particularly among patients previously unable to access routine NHS dentistry.

The centre's location in Gloucester City also reflects the ICB's intention to address inequalities in access.

A second dental hub is planned for 2027

In April 2026, the ICB and University of Gloucestershire announced a new Three Counties Dental School and Treatment Hub at the University's City Campus.

The plan includes six treatment rooms, evening and weekend urgent care, treatment plans, eligible routine appointments, oral-health promotion and training opportunities. The April 2026 ICB announcement gave spring 2027 as the intended start for the treatment hub, while a July 2026 ICB news item referred to an opening later in 2026. The dates conflict; confirm the latest delivery timetable before treating the hub as operational or scheduling market entry around it.

This is planned capacity, not a facility confirmed operational in October 2026. Its implementation and current status need checking against updated official information.

Its significance is both clinical and commercial: Gloucestershire is addressing dental access partly through direct investment and workforce development. New entrants should consider the future supply pipeline, not only today's reported difficulties.

The 2026 GP Patient Survey provides an important counterweight

The ICB's July 2026 publication reported overall GP satisfaction at 81%, pharmacy experience at 89% and dental experience at 69%.

• 81%GP practices
• 89%Community pharmacy
• 69%NHS dental services

These figures suggest that Gloucestershire's access challenges are uneven. The relatively lower dental result is consistent with the ICB's substantial programme to improve dentistry, while general practice compares favourably with the national satisfaction benchmark.

Survey results do not measure every dimension of clinical quality or unmet need. But they prevent a misleading narrative in which every part of local primary care is described as uniformly undersupplied.

Private GP and diagnostics: define the problem being solved

Gloucestershire has a population capable of supporting private healthcare activity in some segments, but a business case cannot be based on affluence alone.

Potential demand might involve same-day access, continuity, workplace health, diagnostics, dermatology, women's health, musculoskeletal services or long-term-condition reviews.

Each service faces a different mix of NHS provision, private competitors and regulatory obligations. A private GP service must be clear whether patients are purchasing speed, appointment length, continuity or an investigation not readily available through their usual pathway.

For diagnostics, the commissioning plan's commitment to earlier community-based testing means future NHS provision may change the market. Providers should identify whether they are selling directly to patients, contracting with an NHS body or supplying another clinical organisation.

Mental health and neurodevelopmental care require pathway scrutiny

Demand for mental-health and neurodevelopmental assessment is often cited as a private healthcare opportunity.

The relevant question is whether local people face unmet need for a particular service, at a particular age, under a particular referral or funding pathway. Assessment, prescribing, ongoing monitoring and post-diagnostic support are different activities with different staffing and governance requirements.

Providers should assess NHS waiting-time evidence, local referral criteria, workforce availability, continuity arrangements and whether reports or diagnoses will be accepted by downstream services.

A clinic built solely around initial assessments may have an incomplete commercial and clinical model if it cannot provide appropriate follow-up.

The changing role of neighbourhood health creates partnership opportunities

The 2026–31 commissioning plan proposes Integrated Neighbourhood Teams and more proactive care for people with rising or complex needs.

This may create opportunities for providers offering specialist input, outreach, diagnostics, therapy or services that prevent avoidable hospital attendance.

However, strategic direction should not be confused with an open procurement opportunity. A business should identify the commissioning body, the service specification, whether a contract is available and the quality and data requirements before treating the plan as prospective revenue.

For some businesses, the most realistic route may be subcontracting or collaboration with an established local provider rather than seeking a standalone NHS contract.

Digital delivery can widen reach but does not eliminate access barriers

Digital consultations, remote monitoring and online booking can make some services more convenient. They may be particularly useful for follow-up, medication reviews and selected long-term-condition management.

They do not replace examination, diagnostics, safeguarding or in-person assessment when those are clinically necessary.

Gloucestershire's urban-rural variation also means that digital exclusion, disability, language, connectivity and patient preference must be considered. A service that appears accessible online may still fail people who most need support.

A credible hybrid model defines which patients can safely be managed remotely and how face-to-face escalation works.

The route to NHS-funded work is distinct from CQC registration

CQC registration is a regulatory requirement for relevant activities; it is not an NHS commissioning contract.

A private GP clinic, diagnostic service, dental practice or other healthcare provider may need to register particular regulated activities depending on what it actually delivers. A pharmacy has separate General Pharmaceutical Council and NHS pharmaceutical-list requirements; some services also trigger CQC registration depending on their scope.

A new NHS pharmacy cannot simply begin dispensing NHS prescriptions because its premises are suitable. Pharmaceutical market entry is governed by a distinct legal process informed by the PNA.

Similarly, NHS dentistry requires the appropriate contractual arrangements. Clinical competence, registration, premises and commissioning are related but separate tests.

Commercial due diligence for each primary-care model

The table is an independent interpretation of published evidence, not a commissioning guarantee or a council ranking.

What to investigate before opening a clinic

A prospective provider should start with the precise clinical service, intended patient cohort and catchment.

Then establish the current provider map, referral pathway, existing NHS offer, patient experience, waiting times where reliably measured, expected fee or contract value, workforce requirements and physical premises.

For a proposed pharmacy, read the Gloucestershire 2025–28 PNA and any relevant supplementary statements, not the neighbouring South Gloucestershire assessment. The two authorities have separate Health and Wellbeing Boards and statutory PNA documents.

For dentistry, distinguish routine, urgent, stabilisation and specialist services and account for the new Gloucester centres.

For GP-led and specialist clinics, check local PCN provision and the commissioning plan before assuming a national shortage translates into a viable Gloucestershire business.

The overall primary-care opportunity in Gloucestershire

Gloucestershire has a substantial primary-care infrastructure and a comparatively positive GP patient-experience profile. It also has meaningful local access differences, an ageing population, evolving community-pharmacy activity and a clearly documented programme to improve NHS dentistry.

The most credible new services are likely to solve a specific access, clinical or pathway problem, not simply add another undifferentiated clinic.

The strongest business case will demonstrate who needs the service, why existing provision does not meet that need, how patients will reach it, what they or a commissioner will pay and how the service will remain clinically safe.